
|Videos|June 30, 2021
Efficacy, Safety of an Investigational Dose of Semaglutide Injection in Adults With Type 2 Diabetes
Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the findings around the efficacy and safety of the 2 mg dose of semaglutide for the treatment of type 2 diabetes.
Advertisement
Pharmacy Times interviewed Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, on results from the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide (Ozempic; Novo Nordisk) injection in adults with type 2 diabetes.
During the discussion, Radin addresses the findings around the efficacy and safety of the 2 mg dose of semaglutide among this patient population.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Halfway There Is Nowhere
2
ADA 2026: Key Pharmacotherapy Advances in Type 1 and Type 2 Diabetes
3
CagriSema Outperforms Semaglutide in Lowering HbA1C, Reducing Weight Across REIMAGINE Trials
4
Metformin Cuts Long COVID Risk by 50%, New Trial Confirms
5


















































































































